ReviewPharmacoEconomics2001
Cost effectiveness of treatment options in advanced breast cancer in the UK.
Review in PharmacoEconomics, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 4 syntheses or guidelines pooled it, 88 citations in OpenAlex.
- A Meta-Analysis of the Efficacy of Albumin Paclitaxel versus Docetaxel in the Treatment of Breast Cancer.Journal of healthcare engineering · 2021Pooled it
- Cost-Effectiveness Analysis of Vedolizumab Compared With Infliximab in Anti-TNF-α-Naïve Patients With Moderate-to-Severe Ulcerative Colitis in China.Frontiers in public health · 2021Pooled it
- A systematic review of utility values for chemotherapy-related adverse events.PharmacoEconomics · 2013Pooled it
- Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis.BMC cancer · 2011Pooled it
- Impact of Adverse Events on Health Utility and Health-Related Quality of Life in Patients Receiving First-Line Chemotherapy for Metastatic Breast Cancer: Results from the SELECT BC Study.PharmacoEconomics · 2018Trial
- Cost-utility analysis of survival with epoetin-alfa versus placebo in stage IV breast cancer.PharmacoEconomics · 2003Trial
- Cost Effectiveness of Sequencing Vedolizumab as First-Line Biologic in Ulcerative Colitis and Crohn's Disease in Canada: An Analysis Using Real-World Evidence from the EVOLVE Study.PharmacoEconomics - open · 2025Article
- Cost-utility analysis of genomic profiling in early breast cancer in Colombia.Cost effectiveness and resource allocation : C/E · 2023Article
- Article
- Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom.The European journal of health economics : HEPAC : health economics in prevention and care · 2018Article
- Cost-effectiveness of ustekinumab in moderate to severe Crohn's disease in Sweden.Cost effectiveness and resource allocation : C/E · 2018Article
- Reviewing the quality, health benefit and value for money of chemotherapy and targeted therapy for metastatic breast cancer.Breast cancer research and treatment · 2017Review
- Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma.PharmacoEconomics · 2017Article
- Economic evaluation of brentuximab vedotin for persistent Hodgkin lymphoma.Current oncology (Toronto, Ont.) · 2017Article
- Cost-effectiveness of vedolizumab compared with conventional therapy for ulcerative colitis patients in the UK.ClinicoEconomics and outcomes research : CEOR · 2017Article
- Cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma in Canada.Current oncology (Toronto, Ont.) · 2016Article
- Cost-effectiveness of enzyme replacement therapy for type 1 Gaucher disease.Orphanet journal of rare diseases · 2014Article
- Health-related quality of life anticipated with different management strategies for febrile neutropenia in adult cancer patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2012Article
- Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: A retrospective study.Experimental and therapeutic medicine · 2011Article
- Cost effectiveness of outpatient treatment for febrile neutropaenia in adult cancer patients.British journal of cancer · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo compare clinical and economic study data for docetaxel, paclitaxel and vinorelbine in the treatment of anthracycline-resistant advanced breast cancer. STUDY DESIGN AND
methodsA Markov decision-analysis model to simulate the clinical course of a 'typical' patient with advanced breast cancer during salvage chemotherapy was updated with response rates and adverse effect rates from phase III clinical trial data for docetaxel, paclitaxel and vinorelbine. Costs were taken from UK national databases and hospitals. Utilities were estimated from 30 oncology nurses in the UK using the standard gamble method. PERSPECTIVE: National Health Service.
resultsWhen compared with other chemotherapeutic agents, docetaxel has been shown to increase response rate, time to progression and survival in patients with advanced breast cancer. In the base-case analysis, the incremental cost-utility ratio for docetaxel versus paclitaxel was pound1995 per quality-adjusted life year (QALY) gained (1998 values). The incremental cost-utility ratio for docetaxel versus vinorelbine was pound14 055 per QALY gained. In the comparison with vinorelbine, docetaxel provided the equivalent of an additional 92 days of perfect health. Sensitivity analyses confirmed the robustness of the model and the validity of the base-case analysis results. Even in the worst case scenarios, docetaxel remained cost effective compared with paclitaxel and vinorelbine.
conclusionsThese findings support the use of the taxoids, notably docetaxel, in the management of advanced breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.